Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protara Therapeutics (TARA) Common Equity (2016 - 2026)

Protara Therapeutics' Common Equity history spans 14 years, with the latest figure at $181.2 million for Q1 2026.

  • Quarterly Common Equity rose 14.34% to $181.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $181.2 million through Mar 2026, up 14.34% year-over-year, with the annual reading at $196.4 million for FY2025, 17.52% up from the prior year.
  • Common Equity came in at $181.2 million for Q1 2026, down from $196.4 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $196.4 million in Q4 2025 to a low of $58.4 million in Q1 2024.
  • The 5-year median for Common Equity is $132.3 million (2025), against an average of $122.1 million.
  • Year-over-year, Common Equity plummeted 44.71% in 2023 and then surged 171.35% in 2025.
  • Protara Therapeutics' Common Equity stood at $102.1 million in 2022, then tumbled by 33.07% to $68.3 million in 2023, then surged by 144.63% to $167.1 million in 2024, then grew by 17.52% to $196.4 million in 2025, then decreased by 7.74% to $181.2 million in 2026.
  • Per Business Quant, the three most recent readings for TARA's Common Equity are $181.2 million (Q1 2026), $196.4 million (Q4 2025), and $132.3 million (Q3 2025).